High-throughput GlueSEEKER platform expands druggable space by identifying novel induced protein-protein interactions

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company advancing degrader therapeutics in oncology and inflammation, today published new data validating its GlueSEEKER platform’s ability to accelerate molecular glue drug discovery.

The study, “Systematic molecular glue drug discovery with a high-throughput effector protein remodeling platform,” published on BioRxiv, details how GlueSEEKER engineers effector proteins—such as E3 ligases—at scale to expand protein surface landscapes and induce targeted protein degradation. This platform combines high-throughput biological data with cutting-edge computational drug discovery, enabling rational design of novel molecular glues.

Dr Benedict Cross, CTO of PhoreMost, said, “Molecular glues are an effective therapeutic modality, yet discovery has largely been serendipitous. GlueSEEKER enables rational and systematic design from almost any E3 ligase or target. This study validates our deep mutational scanning approach, marking a significant milestone for drug discovery.”

PhoreMost CEO Dr Neil Torbett added, “FDA-approved molecular glues have already transformed patient outcomes and generated billions in revenue. Our GlueSEEKER platform accelerates discovery across diverse E3 ligases, unlocking new therapeutic targets.”

He continued, “Built on our expertise in mini-protein engineering and high-throughput screening, GlueSEEKER provides rich biological data that fuels AI-driven molecule design. We are excited to advance next-generation molecular glue degrader assets internally and through partnerships.”